WEBULL
News
FBIOP
14.08
-0.49%
-0.07
Weekly Report: what happened at FBIOP last week (0223-0227)?
Weekly Report · 3d ago
12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga · 02/23 17:05
Cyprium Therapeutics Agrees to Sell Priority Review Voucher for $205 Million
Reuters · 02/23 14:28
UPDATE: FORTRESS BIOTECH’S SUBSIDIARY CYPRIUM THERAPEUTICS ENTERS INTO AGREEMENT TO SELL RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER FOR $205 MILLION
Reuters · 02/23 14:24
Cyprium Therapeutics agrees to sell rare pediatric disease priority review voucher for $205 million
Reuters · 02/23 13:31
Fortress Biotech unit Cyprium to sell priority review voucher for $205 million
Reuters · 02/23 13:30
FORTRESS BIOTECH INC - CYPRIUM ELIGIBLE FOR ROYALTIES ON NET SALES OF ZYCUBO, $129 MLN IN MILESTONES
Reuters · 02/23 13:30
FORTRESS BIOTECH INC - CYPRIUM TO PAY 20% OF PRV SALE PROCEEDS TO NIH INSTITUTE
Reuters · 02/23 13:30
Avenue Therapeutics licenses ATX-04 worldwide for Pompe disease
Reuters · 02/23 13:05
AVENUE THERAPEUTICS ENTERS INTO EXCLUSIVE WORLDWIDE LICENSE AGREEMENT FOR ATX-04 FOR THE TREATMENT OF POMPE DISEASE
Reuters · 02/23 13:00
Weekly Report: what happened at FBIOP last week (0216-0220)?
Weekly Report · 02/23 09:38
Weekly Report: what happened at FBIOP last week (0209-0213)?
Weekly Report · 02/16 09:38
Weekly Report: what happened at FBIOP last week (0202-0206)?
Weekly Report · 02/09 09:39
Weekly Report: what happened at FBIOP last week (0126-0130)?
Weekly Report · 02/02 09:38
Weekly Report: what happened at FBIOP last week (0119-0123)?
Weekly Report · 01/26 09:39
Weekly Report: what happened at FBIOP last week (0112-0116)?
Weekly Report · 01/19 09:42
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 01/13 17:05
BUZZ-U.S. STOCKS ON THE MOVE-Albemarle, Lowe's, nLIGHT
Reuters · 01/13 15:42
FORTRESS BIOTECH SHARES HIT NEAR TWO-WEEK LOW, LAST DOWN 6.6%
Reuters · 01/13 14:46
Cyprium Therapeutics Wins FDA Approval for ZYCUBO in Menkes Disease
Reuters · 01/13 14:20
More
Webull provides a variety of real-time FBIOP stock news. You can receive the latest news about Fortress Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About FBIOP
Fortress Biotech, Inc. is a biopharmaceutical company focused on acquiring and advancing assets. The Company has eight marketed prescription pharmaceutical products and over 20 programs in development, with its majority-owned and majority-controlled partners and subsidiaries and partners and subsidiaries it founded and in which it holds significant minority ownership positions. Its portfolio is being commercialized and developed for various therapeutic areas, including oncology, dermatology, and rare diseases. Its dermatology products include Emrosi, Qbrexza, Amzeeq, Zilxi, Exelderm, Targadox, and Luxamend. Its late-stage product candidates include CUTX-101 (copper histidinate injection for Menkes disease), Triplex (cytomegalovirus (CMV) vaccine), and CAEL-101 (monoclonal antibody for AL amyloidosis). Its early and mid-stage product candidates include Dotinurad (urate transporter (URAT1) inhibitor for gout), MB-101 (IL13Rα2 CAR T Cell Program for Glioblastoma), and others.